Pairwise post hoc comparisons revealed that the GLP-1RA group exhibited significantly greater reductions in both UACR and sCD36 levels compared to the insulin and control groups (all p < 0.05), highlighting the superior renoprotective potential of GLP-1RA therapy in the management of DKD. Here, INS is linked to diabetic kidney disease.